[
    [
        {
            "time": "",
            "original_text": "一批药企布局新领域：国控、华润、恒瑞",
            "features": {
                "keywords": [
                    "药企",
                    "布局",
                    "新领域",
                    "国控",
                    "华润",
                    "恒瑞"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "一批药企布局新领域：国控、华润、恒瑞",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "全国集采加速推进 华海药业有望迎来估值修复",
            "features": {
                "keywords": [
                    "全国集采",
                    "加速推进",
                    "华海药业",
                    "估值修复"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "全国集采加速推进 华海药业有望迎来估值修复",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复旦张江研发合作或存利益输送 商业贿赂“旧伤”曝光“泰凌系”历史合作之谜",
            "features": {
                "keywords": [
                    "复旦张江",
                    "研发合作",
                    "利益输送",
                    "商业贿赂",
                    "泰凌系",
                    "历史合作"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复旦张江研发合作或存利益输送 商业贿赂“旧伤”曝光“泰凌系”历史合作之谜",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "维亚生物抽升8% 就收购朗华制药股权支付按金",
            "features": {
                "keywords": [
                    "维亚生物",
                    "抽升",
                    "收购",
                    "朗华制药",
                    "股权支付",
                    "按金"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "维亚生物抽升8% 就收购朗华制药股权支付按金",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明生物低开近3% 遭大股东配售6000万股",
            "features": {
                "keywords": [
                    "药明生物",
                    "低开",
                    "大股东",
                    "配售",
                    "6000万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明生物低开近3% 遭大股东配售6000万股",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]